Top-Rated StocksTop-RatedNASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $24.34 +0.31 (+1.29%) Closing price 03/10/2025 04:00 PM EasternExtended Trading$24.36 +0.02 (+0.10%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Dianthus Therapeutics Stock (NASDAQ:DNTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dianthus Therapeutics alerts:Sign Up Key Stats Today's Range$23.39▼$24.7550-Day Range$19.21▼$27.0452-Week Range$18.13▼$33.77Volume228,439 shsAverage Volume224,808 shsMarket Capitalization$720.39 millionP/E RatioN/ADividend YieldN/APrice Target$46.83Consensus RatingBuy Company OverviewDianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Read More… Remove Ads Dianthus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreDNTH MarketRank™: Dianthus Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 743rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingDianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDianthus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Dianthus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -9.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -9.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.91% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 23.3, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently decreased by 10.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted26.91% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 23.3, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently decreased by 10.15%, indicating that investor sentiment is improving significantly. News and Social Media1.0 / 5News Sentiment-0.26 News SentimentDianthus Therapeutics has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dianthus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.56% of the stock of Dianthus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNTH Stock News HeadlinesDianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of DirectorsMarch 5, 2025 | globenewswire.comDianthus Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 26, 2025 | globenewswire.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.March 11, 2025 | Crypto Swap Profits (Ad)Stifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)February 10, 2025 | markets.businessinsider.comDianthus Therapeutics to Webcast Presentations at Two Investor ConferencesJanuary 30, 2025 | globenewswire.comDianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comTD Cowen Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy RecommendationDecember 21, 2024 | msn.comForecasting The Future: 5 Analyst Projections For Dianthus TherapeuticsDecember 20, 2024 | benzinga.comSee More Headlines DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $21.80 at the start of the year. Since then, DNTH shares have increased by 11.7% and is now trading at $24.34. View the best growth stocks for 2025 here. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.01. The business earned $1.86 million during the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative trailing twelve-month return on equity of 21.68%. Who are Dianthus Therapeutics' major shareholders? Dianthus Therapeutics' top institutional investors include FMR LLC (15.00%), Avidity Partners Management LP (9.71%), Bain Capital Life Sciences Investors LLC (9.09%) and Octagon Capital Advisors LP (7.13%). Insiders that own company stock include Fairmount Funds Management Llc and Simrat Randhawa. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dianthus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/08/2024Today3/11/2025Next Earnings (Estimated)3/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DNTH CIK1690585 Webdianthustx.com Phone857-242-0170FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$46.83 High Stock Price Target$58.00 Low Stock Price Target$36.00 Potential Upside/Downside+92.4%Consensus RatingBuy Rating Score (0-4)3.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,560,000.00 Net Margins-1,250.32% Pretax Margin-1,250.32% Return on Equity-21.68% Return on Assets-20.88% Debt Debt-to-Equity RatioN/A Current Ratio18.30 Quick Ratio18.30 Sales & Book Value Annual Sales$5.37 million Price / Sales134.25 Cash FlowN/A Price / Cash FlowN/A Book Value$11.40 per share Price / Book2.14Miscellaneous Outstanding Shares29,597,000Free Float24,696,000Market Cap$720.39 million OptionableOptionable Beta1.82 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:DNTH) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.